Clinical Genotyping of Non–Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes

Neoplasia (United States)

Volumn 18, Issue 9, 2016, Pages 577-583

  Tafe, Laura J ^a   Pierce, Kirsten J ^a   Peterson, Jason D ^a   de Abreu, Francine ^a   Memoli, Vincent A ^a   Black, Candice C ^a   Pettus, Jason R ^a   Marotti, Jonathan D ^a   Gutmann, Edward J ^a   Liu, Xiaoying ^a   Shirai, Keisuke ^a   Dragnev, Konstantin H ^a   Amos, Christopher I ^a   Tsongalis, Gregory J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PIK3CA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CLINICAL LABORATORY; CYTOLOGY; DNA SEQUENCE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE N RAS; PRIORITY JOURNAL; TUMOR BIOPSY; ALLELE; BIOPSY; CELL TRANSFORMATION; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; METASTASIS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; ONCOGENE; PATHOLOGY;

ALLELES; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; ONCOGENES;

EID: 84992213004     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.07.010     Document Type: Article

References (24)

1. [1] Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., (eds.) WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed., 2015, IAEC, Lyon.
2. [2] Cancer Genome Atlas Research Network, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
3. [3] Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
4. [4] Lindeman, NI, Cagle, PT, Beasley, MB, Chitale, DA, Dacic, S, Giaccone, G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137 (2013), 828–860.
5. [5] National Comprehensive Cancer Network, NCCN Guidelines Version 4. 2015.
6. [6] Kris, MG, Johnson, BE, Berry, LD, Kwiatkowski, DJ, Iafrate, AJ, Wistuba, II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
7. [7] Tsongalis, GJ, Peterson, JD, de Abreu, FB, Tunkey, CD, Gallagher, TL, Strausbaugh, LD, et al. Routine use of the Ion Torrent Ampliseq(™) Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 52 (2014), 707–714.
8. [8] De Abreu, FB, Peterson, JD, Amos, CI, Wells, WA, Tsongalis, GJ, Effective quality management practices in routine clinical next generation sequencing. Clin Chem Lab Med, 2016 [Epub ahead of print].
9. [9] Hagemann, IS, O'Neill, PK, Erill, I, Pfeifer, JD, Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. Cancer Genet 208 (2015), 441–447.
10. [10] Dogan, S, Shen, R, Ang, DC, Johnson, ML, D'Angelo, SP, Paik, PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18 (2012), 6169–6177.
11. [11] Massarelli, E, Johnson, FM, Erickson, HS, Wistuba, II, Papadimitrakopoulou, V, Uncommon epidermal growth factor receptor mutations in non–small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80 (2013), 235–241.
12. [12] Yang, JC, Sequist, LV, Geater, SL, Tsai, CM, Mok, TS, Schuler, M, Yamamoto, N, Yu, CJ, Ou, SH, Zhou, C, et al. Clinical activity of afatinib in patients with advanced non–small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16 (2015), 830–838.
13. [13] Tafe, LJ, Tsongalis, GJ, A 78-year-old woman with brain metastases. Clin Chem 61 (2015), 584–586.
14. [14] Vivanco, I, Robins, HI, Rohle, D, Campos, C, Grommes, C, Nghiemphu, PL, et al. Differential sensitivity of glioma- versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2 (2012), 458–471.
15. [15] Li, BT, Lee, A, O'Toole, S, Cooper, W, Yu, B, Chaft, JE, Arcila, ME, Kris, MG, Pavlakis, N, HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib. Lung Cancer 90 (2015), 617–619.
16. [16] Arcila, ME, Nafa, K, Chaft, JE, Rekhtman, N, Lau, C, Reva, BA, Zakowski, MF, Kris, MG, Ladanyi, M, EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12 (2013), 220–229.
17. [17] Li, BT, Ross, DS, Aisner, DL, Chaft, JE, Hsu, M, Kako, SL, Kris, MG, Varella-Garcia, M, Arcila, ME, HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol 11 (2016), 414–419.
18. [18] Carter, J, Tseng, LH, Zheng, G, Dudley, J, Illei, P, Gocke, CD, et al. Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. Am J Clin Pathol 144 (2015), 620–628.
19. [19] Gautschi, O, Peters, S, Zoete, V, Aebersold-Keller, F, Strobel, K, Schwizer, B, et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 82 (2013), 365–367.
20. [20] Sen, B, Peng, S, Tang, X, Erickson, HS, Galindo, H, Mazumdar, T, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med, 4, 2012, 136ra70.
21. [21] Tafe, LJ, Gorlov, IP, de Abreu, FB, Lefferts, JA, Liu, X, Pettus, JR, et al. Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center. Oncologist 20 (2015), 1011–1018.
22. [22] Eng, J, Woo, KM, Sima, CS, Plodkowski, A, Hellmann, MD, Chaft, JE, et al. Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas. J Thorac Oncol 10 (2015), 1713–1719.
23. [23] Pécuchet, N, Laurent-Puig, P, Mansuet-Lupo, A, Legras, A, Alifano, M, Pallier, K, et al. Different prognostic impact of STK11 mutations in non-squamous non–small-cell lung cancer. Oncotarget, 2015 [Epub ahead of print].
24. [24] Skoulidis, F, Byers, LA, Diao, L, Papadimitrakopoulou, VA, Tong, P, Izzo, J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5 (2015), 860–877.